Pharmaceuticals & Biotechnology
Executive Search
Our Pharma & Biotech Practice
India is the world's largest provider of generic medicines — supplying 20% of global generic volume and 60% of global vaccine production. This global leadership position, combined with an accelerating domestic market, a growing innovation and biotech sector, and significant CDMO/CRO business opportunities, makes pharmaceutical and biotechnology one of the most dynamic and globally significant sectors in which we operate.
Our Pharma & Biotech practice at Gladwin International Leadership Advisors covers the complete pharmaceutical and life sciences value chain: innovator multinationals, Indian generic leaders, branded generics, biotech companies, vaccine manufacturers, CROs and clinical research organisations, CDMOs, and health-tech companies at the intersection of pharma and digital. We place C-suite and senior leaders across commercial, regulatory, scientific, manufacturing, and business development functions.
Critical to our practice is deep regulatory intelligence. Leaders in pharmaceuticals must navigate a complex matrix of global regulatory requirements (USFDA, EMA, WHO-GMP, CDSCO, ANVISA, PMDA) and our consultants understand the specific competency demands this creates. We have built strong relationships with regulatory affairs, quality assurance, and manufacturing excellence leaders who combine deep technical expertise with commercial acumen.
The Pharma & Biotech Landscape Today
India's pharmaceutical market is $50 billion domestically, with $25 billion in exports. The US remains the largest export market, accounting for 30% of exports, though USFDA compliance pressures continue to be a leadership challenge. Biosimilars and specialty pharma are high-growth areas, with significant R&D investment by companies like Biocon, Serum, Cipla, Sun Pharma, and Dr. Reddy's. The CDMO business is surging, driven by global supply chain diversification away from China. Biotech and gene therapy are early-stage but attracting significant investment. Digital health integration — AI drug discovery, precision medicine, digital therapeutics — is creating new leadership roles at the intersection of pharma and technology.
Key Leadership Challenges in Pharma & Biotech
USFDA and EMA compliance — finding quality and regulatory leaders who can restore and maintain approval status for facilities under import alert or warning letter, one of the sector's most acute leadership demands
Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
CDMO scale-up — as global pharma companies diversify manufacturing into India, building world-class CDMO leadership with both technical excellence and customer relationship management
R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership
Digital transformation in pharma — AI-assisted drug discovery, clinical trial optimisation, and commercial analytics require technology-fluent leaders in a traditionally conservative sector
Market access and pricing — as governments globally drive price controls, finding leaders who can manage market access, pricing strategy, and government affairs with sophistication
Roles We Typically Place
Why Gladwin International Leadership Advisors for Pharma & Biotech
Comprehensive pharma network: Sun Pharma, Cipla, Dr. Reddy's, Lupin, Biocon, Aurobindo, Torrent, Glenmark, and 50+ pharma companies
MNC pharma India operations: Pfizer, Novartis, Roche, AstraZeneca, Abbott, and all major innovator companies
Regulatory affairs and quality specialisation — our most in-demand sub-practice given endemic USFDA compliance challenges
CDMO and CRO practice — placements at Divi's Laboratories, Syngene, Piramal, LifeSciences Pharma, Laurus Labs
Biotech and emerging therapeutics — track record with Serum Institute, Bharat Biotech, Biological E, and biotech startups
Organisations We Serve
Indian generic and branded pharma companies
Multinational pharma MNC India operations
CDMOs and contract manufacturing organisations
CROs and clinical research organisations
Biotech, biosimilar, and specialty pharma companies
Discuss a Mandate
Speak with our Pharma & Biotech practice lead today for a confidential conversation.
Get in TouchUSFDA compliance and quality leadership — one of India's most critical pharma leadership needs
CDMO and CRO practice — specialist coverage as India captures global manufacturing diversification
Biotech and biosimilar emerging practice — early mover in a high-growth sub-sector
Looking for a Pharma & Biotech Leader?
Our Pharma & Biotech practice is ready to help. Guaranteed placement · 12-month candidate guarantee · Affordable pricing for organisations across the value chain.
Frequently Asked Questions — Pharmaceuticals & Biotechnology Executive Search
Common questions about recruiting Pharmaceuticals & Biotechnology leadership in India.
Our Pharmaceuticals & Biotech practice combines deep scientific and commercial understanding with an extensive network of senior pharma leaders — spanning regulated markets, emerging markets, branded generics, API manufacturing, CDMO, medical affairs, and regulatory affairs. We assess candidates across both the scientific and commercial dimensions, understanding that pharma leadership requires fluency across R&D pipelines, regulatory strategy, global manufacturing quality, and complex commercial organisation management.
We fill the full leadership spectrum: CEO/MD, CFO, COO, Chief Scientific Officer, Head of R&D, Head of Regulatory Affairs, Head of Medical Affairs, Head of Clinical Operations, Head of Quality & Compliance, Head of Manufacturing, Head of Commercial Operations, Head of International Business, CHRO, and Board Directors. We serve Indian pharma majors, MNC pharma subsidiaries, biotech companies, CROs, CDMOs, and API manufacturers.
The most effective pharmaceutical leaders in India today combine regulatory mastery with commercial excellence. They navigate USFDA, EMA, and WHO audit environments while driving market share across branded generics, patented products, or API supply chains. Key competencies include quality culture leadership (critical in an era of USFDA warning letters), talent management in highly specialised scientific functions, and portfolio strategy across regulated and emerging markets. Increasingly, digital health and RWE (real-world evidence) fluency is becoming a differentiator.
Yes. Our pharma practice serves biotech startups, research institutions, gene therapy companies, biosimilar developers, and innovative drug discovery organisations. These mandates typically require leaders who combine scientific credibility with fundraising capability, board management skills, and the ability to build research cultures that attract top scientific talent. We maintain strong networks in India's growing biotech hubs — Hyderabad, Pune, Bengaluru, and Ahmedabad.
CEOs of mid-to-large Indian pharma companies typically earn ₹3–10 crore CTC with performance bonuses. Country heads of MNC pharma subsidiaries typically command ₹3–7 crore. Heads of R&D at major pharma companies typically earn ₹1.5–4 crore. Quality and Regulatory Affairs heads command a significant premium given the USFDA compliance environment, typically earning ₹1.5–3.5 crore. We provide current, role-specific pharma compensation benchmarks for every search mandate.